Literature DB >> 2535999

Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas.

K Y Terada1, T L Johnson, M Hopkins, J A Roberts.   

Abstract

Over a 27-year period there were 15 patients treated at the University of Michigan Medical center for carcinosarcomas or mixed mesodermal tumors of the ovary. Overall median survival was 11 months. Median survival was 4 months in patients with carcinosarcomas and 13 months in patients with mixed mesodermal tumors (P = 0.066). Patients with a chondrosarcomatous element had a significantly longer median survival than patients with mixed mesodermal tumors lacking cartilaginous differentiation (P = 0.031). The presence of a rhabdomyosarcomatous element did not affect survival. The size of the primary tumor, presence of ascites, FIGO stage, and degree of initial resection (optimal versus suboptimal) did not affect survival. There was no difference in survival between patients receiving postoperative chemotherapy and patients undergoing postoperative irradiation.

Entities:  

Mesh:

Year:  1989        PMID: 2535999     DOI: 10.1016/s0090-8258(89)80038-1

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.

Authors:  Federica Guzzo; Stefania Bellone; Natalia Buza; Pei Hui; Luisa Carrara; Joyce Varughese; Emiliano Cocco; Marta Betti; Paola Todeschini; Sara Gasparrini; Peter E Schwartz; Thomas J Rutherford; Roberto Angioli; Sergio Pecorelli; Alessandro D Santin
Journal:  Int J Gynecol Pathol       Date:  2012-05       Impact factor: 2.762

Review 2.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

3.  Carcinosarcoma of the ovary.

Authors:  M A Harris; L M Delap; P S Sengupta; P M Wilkinson; R S Welch; R Swindell; J H Shanks; G Wilson; R J Slade; K Reynolds; G C Jayson
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.